유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
kepivance
swedish orphan biovitrum ab (publ) - palifermiin - mukosiit - kõik muud ravitoimingud - kepivance on näidustatud vähenenud esinemissageduse, kestuse ja raskusastme esinemissageduse täiskasvanud patsientidel, kes saavad müeloablatiivset radiochemotherapy seotud koosnevaid raske mukosiit ja nõuavad autoloogne---vereloome tugi.
에스토니아 -
에스토니아어 -
Ravimiamet
carboplatin pfizer infusioonilahuse kontsentraat
pfizer enterprises sarl - karboplatiin - infusioonilahuse kontsentraat - 10mg 1ml 45ml 1tk